Last reviewed · How we verify
NCT06903429: LUCAS
Using LUminoMark vs Coventional Practice for Targeted Axillary Surgery
NA trial testing Targeting of axillary lymph nodes using LuminoMark in Breast Cancer in 330 participants. Not yet recruiting.
31 December 2026
Quick facts
| Lead sponsor | Kyungpook National University Chilgok Hospital |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 330 |
| Start date | 1 May 2025 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2027 |
Drugs / interventions tested
- Targeting of axillary lymph nodes using LuminoMark
- Targeting of axillary lymph nodes using conventional method
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Axillary Lymph Nodes — all drugs for Axillary Lymph Nodes →
- Target Lesion — all drugs for Target Lesion →
Sponsor
Kyungpook National University Chilgok Hospital
Who can join
Adults 20 to 70, any sex, with Breast Cancer or Axillary Lymph Nodes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study was to compare the use of LuminoMarkTM as a method of targeting axillary lymph nodes with other existing methods used in each institution, such as charcoal staining, needle targeting, and ultrasound-guided skin marking, in patients with breast cancer clinically suspected of metastasis, with or without clipping at the time of diagnosis, regardless of the presence or absence of neoadjuvant chemotherapy. By doing so, the investigators aimed to confirm the safety and usefulness of LuminoMarkTM as a targeting method.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06903429
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Kyungpook National University Chilgok Hospital trials
Trials by the same sponsor.
- NCT07066800 — Mindfulness Intervention for Maltreatment-Related Cognitive Decline · NA · active not recruiting
- NCT07511998 — A Randomized, Comparative, Controlled Study of Differences in the Incidence of Postoperative Sore Throat (POST) by Inner · NA · enrolling by invitation
- NCT06162390 — Optimal Concentration of Remifentanil for NIM Tube Intubation With Low-dose NMBA · NA · completed
- NCT05956054 — A Comparison of Intravascular Penetration With Curved Needle and Straight Needle During S1 STE · NA · unknown
- NCT05543863 — Pharmacokinetics of Oral Antiplatelet Agents After Distal Gastrectomy · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06903429 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kyungpook National University Chilgok Hospital
- Last refreshed: 30 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06903429.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing